Sionna Therapeutics (NASDAQ:SION) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Sionna Therapeutics (NASDAQ:SION) from a hold rating to a sell rating in a research report released on Saturday morning.

A number of other equities analysts also recently weighed in on SION. Wedbush assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. Citizens Jmp assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target on the stock. Citigroup began coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Sionna Therapeutics Stock Performance

Shares of SION opened at $40.22 on Friday. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -20.84 and a beta of 1.35. The company’s 50 day simple moving average is $39.40 and its 200 day simple moving average is $39.54. Sionna Therapeutics has a 1 year low of $12.42 and a 1 year high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Equities analysts expect that Sionna Therapeutics will post -2.53 EPS for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. This represents a 6.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,717,760 shares of company stock valued at $77,562,902. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. TD Asset Management Inc increased its holdings in Sionna Therapeutics by 74.3% in the 3rd quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock valued at $2,561,000 after buying an additional 37,116 shares during the period. Jennison Associates LLC increased its holdings in Sionna Therapeutics by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after buying an additional 117,903 shares during the period. Vanguard Group Inc. increased its holdings in Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after buying an additional 41,797 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Sionna Therapeutics in the 3rd quarter valued at $147,000. Finally, Walleye Capital LLC bought a new stake in Sionna Therapeutics in the 1st quarter valued at $605,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.